Abstract

Avian leukosis virus subgroup J (ALV-J) is an oncogenic virus causing hemangiomas and myeloid tumors in chickens. Interleukin-6 (IL-6) is a multifunctional pro-inflammatory interleukin involved in many types of cancer. We previously demonstrated that IL-6 expression was induced following ALV-J infection in chickens. The aim of this study is to characterize the mechanism by which ALV-J induces IL-6 expression, and the role of IL-6 in tumor development. Our results demonstrate that ALV-J infection increases IL-6 expression in chicken splenocytes, peripheral blood lymphocytes, and vascular endothelial cells. IL-6 production is induced by the ALV-J envelope protein gp85 and capsid protein p27 via PI3K- and NF-κB-mediated signaling. IL-6 in turn induced expression of vascular endothelial growth factor (VEGF)-A and its receptor, VEGFR-2, in vascular endothelial cells and embryonic vascular tissues. Suppression of IL-6 using siRNA inhibited the ALV-J induced VEGF-A and VEGFR-2 expression in vascular endothelial cells, indicating that the ALV-J-induced VEGF-A/VEGFR-2 expression is mediated by IL-6. As VEGF-A and VEGFR-2 are important factors in oncogenesis, our findings suggest that ALV-J hijacks IL-6 to promote tumorigenesis, and indicate that IL-6 could potentially serve as a therapeutic target in ALV-J infections.

Highlights

  • Avian leukosis virus (ALV) is a highly oncogenic alpha-retrovirus of Retroviridae family, causing avian leukosis (AL) in chickens

  • As we have found that Avian leukosis virus subgroup J (ALV-J) infection promotes IL-6 expression in vivo [28], we hypothesized that IL-6 might be associated with ALV-J pathogenesis

  • In the present study, we have examined the ability of ALV-J to induce the IL-6 expression in vitro, and we have analyzed the biological impact of the induced IL-6

Read more

Summary

Introduction

Avian leukosis virus (ALV) is a highly oncogenic alpha-retrovirus of Retroviridae family, causing avian leukosis (AL) in chickens. Various tumors including hemangiomas induced by ALV-J have emerged among parent and commercial layer flocks [5, 6], leading to enormous economic losses, and indicating an evolution of ALV-J oncogenicity. ALV-J does not carry a viral oncogene. Most studies regarding the ALV-J oncogenicity have focused on the insertional mechanisms of ALV-J, which activates or inactivates the tumorassociated genes of the host [7,8,9,10,11]. As ALV integrates in a largely random fashion with only a slight preference for active transcriptional units [12, 13], there must be some other mechanisms for ALV tumorigenicity

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call